EMEA-000069-PIP02-10-M08

  • Email
  • Help

Overview

Product details for Nucala
Invented nameNucala
Active substance

Mepolizumab

Decision numberP/0239/2017
PIP numberEMEA-000069-PIP02-10-M08
Pharmaceutical form(s)Powder for solution for injection / infusion; Solution for injection
Condition(s)/indication(s)

Treatment of asthma

Route(s) of administrationIntravenous use, Subcutaneous use
PIP applicant

GlaxoSmithKline Trading Services
United Kingdom
Tel . +44 (0)20 8990 3650
E-mail: eu.paediatric-plans@gsk.com

Decision typePM: decision on the application for modification of an agreed PIP
Compliance check procedure numberEMEA-C-000069-PIP02-10-M08
Compliance check opinion date10/11/2017
Compliance check outcomePositive

Decision